Want to see AIDX full AI Analyst Report?
AIDX Stock Chart & Stats
$1.78
--
Market closed
$1.78
--
Day’s Range― - ―
52-Week Range$0.40 - $50.00
Previous CloseN/A
VolumeN/A
Average Volume (3M)N/A
Market Cap
$7.08M
Enterprise Value$4.30
Total Cash (Recent Filing)$4.55M
Total Debt (Recent Filing)$572.45K
Price to Earnings (P/E)―
Beta2.40
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding12,770,303
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Financial Highlights & Ratios
PEG Ratio0.82
Price to Book (P/B)-7.76
Price to Sales (P/S)72.96
P/FCF Ratio-0.08
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Sharp 2025 Revenue ReboundThe 2025 revenue recovery indicates renewed demand or improved commercial execution after the prior downturn. Sustaining this recovery would provide a larger base over which fixed laboratory and reporting costs could be spread.
Improved Gross MarginThe margin improvement suggests a more favorable service mix, pricing profile, or delivery economics. If retained as volumes recover, it could strengthen unit economics and improve the company’s path toward operating breakeven.
Diagnostic Testing PlatformA focus on diagnostic assays and blood-based testing gives the company a defined healthcare testing platform with potential to serve providers and other customers. Continued assay development could support recurring service adoption.
Bears Say
Persistent Unprofitable OperationsPersistent operating and net losses show that revenue and gross-margin gains have not yet covered the broader cost base. Without sustained operating leverage, future growth may continue requiring external funding rather than producing durable earnings.
Severe Cash-flow DeteriorationSeveral years of negative operating and free cash flow weaken internal funding capacity and increase dependence on financing. The exceptionally large 2025 burn raises the risk that expansion, product development, or routine operations require additional capital.
Highly Leveraged, Negative-equity Balance SheetDebt at this scale alongside negative equity materially reduces financial flexibility and increases refinancing and solvency risk. It may constrain investment in assays and testing capacity while making future capital more costly or dilutive.
20/20 Biolabs, Inc. News
AIDX FAQ
What was 20/20 Biolabs, Inc.’s price range in the past 12 months?
20/20 Biolabs, Inc. lowest stock price was $0.40 and its highest was $50.00 in the past 12 months.
What is 20/20 Biolabs, Inc.’s market cap?
20/20 Biolabs, Inc.’s market cap is $7.08M.
When is 20/20 Biolabs, Inc.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were 20/20 Biolabs, Inc.’s earnings last quarter?
Currently, no data Available
Is 20/20 Biolabs, Inc. overvalued?
According to Wall Street analysts 20/20 Biolabs, Inc.’s price is currently Overvalued.
Does 20/20 Biolabs, Inc. pay dividends?
20/20 Biolabs, Inc. does not currently pay dividends.
What is 20/20 Biolabs, Inc.’s EPS estimate?
20/20 Biolabs, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does 20/20 Biolabs, Inc. have?
20/20 Biolabs, Inc. has 12,770,303 shares outstanding.
What happened to 20/20 Biolabs, Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of 20/20 Biolabs, Inc.?
Currently, no hedge funds are holding shares in AIDX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
20/20 Biolabs, Inc.
20/20 GeneSystems, Inc. operates as a clinical laboratory testing company focused on cancer screening and viral testing services. The company provides multi-cancer early detection blood testing, including a test called OneTest, and offers viral testing services such as rapid COVID-19 test kits, including the Assure COVID-19 IgG/IgM rapid test. It operates the Clinical Lab Innovation Axcelerator (CLIAx), a shared laboratory facility that supports diagnostic test developers in bringing products to the U.S. market. The company also delivers its cancer screening algorithm technology through a software as a service (SaaS) platform in partnership with healthcare providers and supports diagnostic startups by offering access to shared laboratory space and resources. The company was founded in 2000 and is based in Gaithersburg, Maryland.
Biomerica
―
Co-Diagnostics
―
Lucid Diagnostics
―
Bluejay Diagnostics
―
Heart Test Laboratories, Inc.
―